Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TOPFIBRO

Financiado

Targeting OGG1 in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies. Approved therapies for IPF have a high rate of discontinuation among patients due to adverse side-effects and present a high unmet need... ver más

30/04/2026

OXCIA AB

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

OXCIA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-16

HORIZON-EIC-2022-TRANSITIONOPEN-01: EIC Transition Open 2022 Expected Impact:At the end of the EIC Transition project, it should be ready for the next stage, whi...

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

OXCIA AB

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FIBROSIS Fibroproliferative Invasive Fibroblasts in Idiopathic Pulmon... 266K€ Cerrado

SAF2017-89908-R ENTENDIENDO EL PAPEL DE LAS CELULAS MADRE DE PULMON EN LA RE... 171K€ Cerrado

PID2020-117888RB-I00 REGULACION DE LA MUERTE CELULAR EN LOS FIBROBLASTOS INDUCIDA... 114K€ Cerrado

SAF2009-13243 DETERMINANTES MECANICOS DE LA FIBROGENESIS PULMONAR ESTUDIAD... 109K€ Cerrado

RTI2018-096827-B-I00 MODULACION FARMACOLOGICA DE LA SEÑALIZACION REDOX EN REMODEL... 97K€ Cerrado

SENFIB Novel senolytic drugs for the treatment of lung and kidney f... 150K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2023-03-16
Fecha Fin: 2026-04-30

Líder del proyecto

OXCIA AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Descripción del proyecto Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung disease with no curative therapies. Approved therapies for IPF have a high rate of discontinuation among patients due to adverse side-effects and present a high unmet need for effective therapies. Oxcia’s OXC-201 is a ground-breaking novel approach for treatment of IPF, based on completely new biology. OXC-201 targets profibrotic and proinflammatory cascades at an early stage on a transcriptional level, and is expected to efficiently prevent lung damage, creating a window for restorative processes to repair scar tissue. OXC-201 has demonstrated significant efficacy in halting disease progression and improved safety and tolerability in preclinical IPF models. In the TOPFIBRO project we will 1) obtain further proof of concept of OXC-201’s efficacy in improving lung function in vivo and confirm antifibrotic efficacy in patient-derived ex vivo models compared to current standard of care, 2) take OXC-201 through preclinical safety assessment studies, 3) fulfill regulatory demands, preparation of IMPD, CTA and ethical applications in order to initiate first-in-human studies, 4) perform first-in-human clinical studies to determine safety profile in healthy volunteers, 5) develop a strong business plan with regulatory, financial and clinical roadmaps to improve investor-readiness. These steps will allow us to further develop OXC-201 with the end goal of bringing it to market via a licensing deal with a large pharmaceutical company. OXC-201 has the potential to fill a large unmet need of the IPF patient community and present the first potentially curative therapy.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores